Literature DB >> 34293298

Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies.

Kristina G Hulten1, Robert M Genta2, Ira N Kalfus3, Yi Zhou4, Hongjun Zhang4, David Y Graham5.   

Abstract

BACKGROUND & AIMS: The decline in Helicobacter pylori cure rates emphasizes the need for readily available methods to determine antimicrobial susceptibility. Our aim was to compare targeted next-generation sequencing (NGS) and culture-based H pylori susceptibility testing using clinical isolates and paired formalin-fixed, paraffin-embedded (FFPE) gastric biopsies.
METHODS: H pylori isolates and FFPE tissues were tested for susceptibility to amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and rifabutin using agar dilution and NGS targeted to 23S rRNA, gyrA, 16S rRNA, pbp1, rpoB and rdxA. Agreement was quantified using κ statistics.
RESULTS: Paired comparisons included 170 isolates and FFPE tissue for amoxicillin, clarithromycin, metronidazole, and rifabutin and 57 isolates and FFPE tissue for levofloxacin and tetracycline. Agreement between agar dilution and NGS from culture isolates was very good for clarithromycin (κ = 0.90012), good for levofloxacin (κ = 0.78161) and fair for metronidazole (κ = 0.55880), and amoxicillin (κ = 0.21400). Only 1 isolate was resistant to tetracycline (culture) and 1 to rifabutin (NGS). Comparison of NGS from tissue blocks and agar dilution from isolates from the same stomachs demonstrated good accuracy to predict resistance for clarithromycin (94.1%), amoxicillin (95.9%), metronidazole (77%), levofloxacin (87.7%), and tetracycline (98.2%). Lack of resistance precluded comparisons for tetracycline and rifabutin.
CONCLUSIONS: Compared with agar dilution, NGS reliably determined resistance to clarithromycin, levofloxacin, rifabutin, and tetracycline from clinical isolates and formalin-fixed gastric tissue. Consistency was fair for metronidazole and amoxicillin. Culture-based testing can predict treatment outcomes with clarithromycin and levofloxacin. Studies are needed to compare the relative ability of both methods to predict treatment outcomes for other antibiotics.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacterial Resistance; Culture; Formalin-Fixed Tissue; Helicobacter pylori; Next-Generation Sequencing

Mesh:

Substances:

Year:  2021        PMID: 34293298      PMCID: PMC9047521          DOI: 10.1053/j.gastro.2021.07.012

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  52 in total

1.  A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori.

Authors:  Takeshi Okamoto; Hironori Yoshiyama; Teruko Nakazawa; In-Dal Park; Myung-Woong Chang; Hideo Yanai; Kiwamu Okita; Mutsunori Shirai
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial.

Authors:  David Y Graham; Yamil Canaan; James Maher; Gregory Wiener; Kristina G Hulten; Ira N Kalfus
Journal:  Ann Intern Med       Date:  2020-05-05       Impact factor: 25.391

3.  Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies.

Authors:  Laisheng Luo; Yu Huang; Xiao Liang; Yingjie Ji; Lou Yu; Hong Lu
Journal:  Helicobacter       Date:  2020-05-19       Impact factor: 5.753

4.  European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners.

Authors:  David Y Graham; Hashem B El-Serag
Journal:  Gut       Date:  2020-09-21       Impact factor: 23.059

5.  European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.

Authors:  Olga P Nyssen; Dmitry Bordin; Bojan Tepes; Ángeles Pérez-Aisa; Dino Vaira; Maria Caldas; Luis Bujanda; Manuel Castro-Fernandez; Frode Lerang; Marcis Leja; Luís Rodrigo; Theodore Rokkas; Limas Kupcinskas; Jorge Pérez-Lasala; Laimas Jonaitis; Oleg Shvets; Antonio Gasbarrini; Halis Simsek; Anthony T R Axon; György Buzás; Jose Carlos Machado; Yaron Niv; Lyudmila Boyanova; Adrian Goldis; Vincent Lamy; Ante Tonkic; Krzysztof Przytulski; Christoph Beglinger; Marino Venerito; Peter Bytzer; Lisette Capelle; Tomica Milosavljević; Vladimir Milivojevic; Lea Veijola; Javier Molina-Infante; Liudmila Vologzhanina; Galina Fadeenko; Ines Ariño; Giulia Fiorini; Ana Garre; Jesús Garrido; Cristina F Pérez; Ignasi Puig; Frederic Heluwaert; Francis Megraud; Colm O'Morain; Javier P Gisbert
Journal:  Gut       Date:  2020-09-21       Impact factor: 23.059

6.  Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori.

Authors:  Emiko Rimbara; Norihisa Noguchi; Takashi Kawai; Masanori Sasatsu
Journal:  J Antimicrob Chemother       Date:  2008-02-14       Impact factor: 5.790

7.  Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori.

Authors:  Monique M Gerrits; Marco Berning; Arnoud H M Van Vliet; Ernst J Kuipers; Johannes G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori.

Authors:  Monique M Gerrits; Marcel R de Zoete; Niek L A Arents; Ernst J Kuipers; Johannes G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

9.  Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials.

Authors:  Mei-Jyh Chen; Ming-Shiang Wu; Chien-Chuan Chen; Chieh-Chang Chen; Yu-Jen Fang; Ming-Jong Bair; Chi-Yang Chang; Ji-Yuh Lee; Wen-Feng Hsu; Jiing-Chyuan Luo; Jaw-Town Lin; Jyh-Ming Liou
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

10.  Susceptibility-guided therapy for Helicobacter pylori infection treatment failures.

Authors:  Lou Yu; Laisheng Luo; Xiaohua Long; Xiao Liang; Yingjie Ji; Qi Chen; Yanyan Song; Xiaobo Li; David Y Graham; Hong Lu
Journal:  Therap Adv Gastroenterol       Date:  2019-09-09       Impact factor: 4.409

View more
  3 in total

Review 1.  Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Clin Microbiol Rev       Date:  2022-04-11       Impact factor: 50.129

Review 2.  Biomarker Characterization and Prediction of Virulence and Antibiotic Resistance from Helicobacter pylori Next Generation Sequencing Data.

Authors:  Joana S Vital; Luís Tanoeiro; Ricardo Lopes-Oliveira; Filipa F Vale
Journal:  Biomolecules       Date:  2022-05-11

Review 3.  Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients.

Authors:  Brian White; Maria Winte; Joshua DeSipio; Sangita Phadtare
Journal:  Microorganisms       Date:  2022-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.